Trial reportJournal of psychiatric research2014
Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
Trial report in Journal of psychiatric research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03220776 (Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics
Who cites it
11 citing papers in PubMed.
- A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.Journal of affective disorders · 2016Trial
- Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.Journal of psychopharmacology (Oxford, England) · 2015Trial
- The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?Current therapeutic research, clinical and experimental · 2019Review
- Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.Frontiers in psychiatry · 2018Review
- The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.Journal of psychopharmacology (Oxford, England) · 2017Article
- Experimental medication treatment approaches for depression.Translational psychiatry · 2017Review
- Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Drugs · 2017Review
- Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Review
- Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.Molecular psychiatry · 2015Review
- A brief history of the development of antidepressant drugs: from monoamines to glutamate.Experimental and clinical psychopharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.